Literature DB >> 20521157

Predicting mortality in patients with community-acquired pneumonia and low CURB-65 scores.

D Ronan1, D Nathwani, P Davey, G Barlow.   

Abstract

Some patients classified as having non-severe community-acquired pneumonia (CAP) by CURB-65 subsequently die. The objective of this study was to identify risk factors for mortality in non-severe patients and to test how risk factors might be used. Patients who had a CURB-65 score of 0-2 on admission to hospital and were alive at 30 days were compared with those who died. Identified risk factors were included in new variations of CURB-65 and new management strategies. Age >65 years, blood urea >7 mmol/l, bilateral/multi-lobar appearance of the chest radiograph (CXR), social situation (living alone/no fixed abode or residential/nursing care) and temperature <36 degrees C were associated with mortality (p < 0.05). A two-step approach, with initial use of CURB-65 followed by the above non-CURB-65 criteria, increased the proportion of patients correctly classified as having severe CAP who subsequently died from 54/76 (71%, 95% confidence interval [CI] 61% to 81%) to 72/76 (95%, 95% CI 90% to 100%). The consideration of additional risk factors in a two-step approach can improve the stratification of mortality by CURB-65. Physicians should be cautious about managing patients with CAP as outpatients if they have a CURB-65 score of 1 (or more) and have at least one of the three additional risk factors identified.

Entities:  

Mesh:

Year:  2010        PMID: 20521157     DOI: 10.1007/s10096-010-0970-7

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  16 in total

1.  BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.

Authors: 
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

2.  High rates of ischaemic heart disease in Scotland are not explained by conventional risk factors.

Authors:  Richard Mitchell; Gerry Fowkes; David Blane; Mel Bartley
Journal:  J Epidemiol Community Health       Date:  2005-07       Impact factor: 3.710

3.  Development and validation of a clinical prediction rule for severe community-acquired pneumonia.

Authors:  Pedro P España; Alberto Capelastegui; Inmaculada Gorordo; Cristobal Esteban; Mikel Oribe; Miguel Ortega; Amaia Bilbao; José M Quintana
Journal:  Am J Respir Crit Care Med       Date:  2006-09-14       Impact factor: 21.405

Review 4.  Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community.

Authors:  Dilip Nathwani; Marina Morgan; Robert G Masterton; Matthew Dryden; Barry D Cookson; Gary French; Deirdre Lewis
Journal:  J Antimicrob Chemother       Date:  2008-03-13       Impact factor: 5.790

5.  Systolic blood pressure is superior to other haemodynamic predictors of outcome in community acquired pneumonia.

Authors:  J D Chalmers; A Singanayagam; A T Hill
Journal:  Thorax       Date:  2008-05-20       Impact factor: 9.139

6.  Prevalence and prognostic implications of dysphagia in elderly patients with pneumonia.

Authors:  Mateu Cabre; Mateu Serra-Prat; Elisabet Palomera; Jordi Almirall; Roman Pallares; Pere Clavé
Journal:  Age Ageing       Date:  2009-06-26       Impact factor: 10.668

Review 7.  Measuring the accuracy of diagnostic systems.

Authors:  J A Swets
Journal:  Science       Date:  1988-06-03       Impact factor: 47.728

8.  Prospective comparison of three predictive rules for assessing severity of community-acquired pneumonia in Hong Kong.

Authors:  Shin Yan Man; Nelson Lee; Margaret Ip; Gregory E Antonio; Shirley S L Chau; Paulina Mak; Colin A Graham; Mingdong Zhang; Grace Lui; Paul K S Chan; Anil T Ahuja; David S Hui; Joseph J Y Sung; Timothy H Rainer
Journal:  Thorax       Date:  2006-11-22       Impact factor: 9.139

9.  SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia.

Authors:  Patrick G P Charles; Rory Wolfe; Michael Whitby; Michael J Fine; Andrew J Fuller; Robert Stirling; Alistair A Wright; Julio A Ramirez; Keryn J Christiansen; Grant W Waterer; Robert J Pierce; John G Armstrong; Tony M Korman; Peter Holmes; D Scott Obrosky; Paula Peyrani; Barbara Johnson; Michelle Hooy; M Lindsay Grayson
Journal:  Clin Infect Dis       Date:  2008-08-01       Impact factor: 9.079

10.  Increasing hospital admissions for pneumonia, England.

Authors:  Caroline L Trotter; James M Stuart; Robert George; Elizabeth Miller
Journal:  Emerg Infect Dis       Date:  2008-05       Impact factor: 6.883

View more
  4 in total

1.  Utility of two biomarkers for directing care among patients with non-severe community-acquired pneumonia.

Authors:  P P España; A Capelastegui; A Bilbao; R Diez; F Izquierdo; M J Lopez de Goicoetxea; J Gamazo; F Medel; J Salgado; I Gorostiaga; J M Quintana
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-08-05       Impact factor: 3.267

Review 2.  Meta-analysis of Calibration, Discrimination, and Stratum-Specific Likelihood Ratios for the CRB-65 Score.

Authors:  Mark H Ebell; Mary E Walsh; Tom Fahey; Maggie Kearney; Christian Marchello
Journal:  J Gen Intern Med       Date:  2019-04-16       Impact factor: 5.128

Review 3.  A literature review of severity scores for adults with influenza or community-acquired pneumonia - implications for influenza vaccines and therapeutics.

Authors:  Katherine Adams; Mark W Tenforde; Shreya Chodisetty; Benjamin Lee; Eric J Chow; Wesley H Self; Manish M Patel
Journal:  Hum Vaccin Immunother       Date:  2021-11-10       Impact factor: 3.452

4.  Biomarker-enhanced triage in respiratory infections: a proof-of-concept feasibility trial.

Authors:  Werner C Albrich; Kristina Rüegger; Frank Dusemund; Philipp Schuetz; Birsen Arici; Alexander Litke; Claudine A Blum; Rita Bossart; Katharina Regez; Ursula Schild; Merih Guglielmetti; Antoinette Conca; Petra Schäfer; Maria Schubert; Sabina de Geest; Barbara Reutlinger; Sarosh Irani; Ulrich Bürgi; Andreas Huber; Beat Müller
Journal:  Eur Respir J       Date:  2013-01-24       Impact factor: 16.671

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.